Skip to main navigation
Angion Biomedica Corp

Angion Biomedica Corp

ANGION IS A LATE-STAGE CLINICAL COMPANY DEVELOPING SMALL MOLECULES TARGETING ACUTE ORGAN INJURY AND CHRONIC FIBROSIS

  • About
    • Executive Management
    • Scientific Advisory Board
    • Board of Directors
  • Our Science
    • HGF/c-Met Pathway
    • Acute Kidney Injury
    • Acute Lung Injury
    • CNS Injury
  • Pipeline
    • ANG-3777
    • ANG-3070
    • ROCK2 Inhibitor
    • CYP11B2 Inhibitor
  • Investors
    • Stock Information
      • Stock Quote & Chart
      • Historic Price Lookup
    • Analyst Coverage
    • Press Releases
    • Events & Presentations
    • SEC Filings
    • Governance
    • Investor Resources
      • Investor Contact
      • Investor FAQs
      • Email Alerts
  • Publications
  • Careers
  • Contact
  • LinkedIn
  • Twitter

Press Releases

Date Title  
February 24, 2021
Angion to Participate in Upcoming March Investment Conferences
PDF Version
February 9, 2021
Angion Biomedica Corp. Announces Closing of $117 Million Initial Public Offering and Concurrent Private Placement, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
PDF Version
February 5, 2021
Angion Biomedica Corp. Announces Pricing of Initial Public Offering of Common Stock and Concurrent Private Placement
PDF Version

Angion - Investor Tools

  • Print Page
  • Email Alerts
  • RSS Feeds

CORPORATE ADDRESS

51 Charles Lindbergh Boulevard
Uniondale, NY 11553

Navigation

  • home
  • about
  • our science
  • pipeline
  • investors
  • publications
  • careers
  • contact

© Angion. All Rights Reserved.
Legal and Privacy Policy

SAN FRANCISCO| NEW YORK | BOSTON

  • LinkedIn
  • Twitter